[Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 5. Leflunomide and mizoribine]

Nihon Naika Gakkai Zasshi. 2011 Oct 10;100(10):2929-35. doi: 10.2169/naika.100.2929.

[Article in Japanese]

Author

Tetsuji Sawada¹

Affiliation

¹ Department of Rheumatology, Tokyo Medical University Hospital, Japan.

PMID: 22175133
DOI: 10.2169/naika.100.2929

No abstract available

Publication types

Review

MeSH terms

Aged
Arthritis, Rheumatoid / drug therapy*
Female
Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Isoxazoles / adverse effects
Isoxazoles / therapeutic use*
Leflunomide
Male
Middle Aged
Molecular Targeted Therapy
Ribonucleosides / adverse effects
Ribonucleosides / therapeutic use*

Substances

Immunosuppressive Agents
Isoxazoles
Ribonucleosides
mizoribine
Leflunomide